Quick Answer Box
- Merck agreed in June 2026 to pay more than $50 million to settle over 200 Gardasil lawsuits, effectively ending most of the litigation.
- Eligibility centers on plaintiffs who developed POTS, POI, or similar autoimmune conditions and had active claims in the MDL or California state court.
- Individual payouts have not been disclosed publicly, since the settlement was reached before any allocation formula was announced.
Case Snapshot
| Detail | Info |
|---|---|
| Court | U.S. District Court, Western District of North Carolina (MDL 3036); Los Angeles Superior Court (California case) |
| Case / MDL Number | MDL No. 3036, In re: Gardasil Products Liability Litigation |
| Filing Date | Cases transferred to MDL on August 4, 2022 |
| Status | Settled in principle as of June 4, 2026; one case not covered |
| Settlement Fund | More than $50 million for over 200 cases |
The Gardasil lawsuit took its most significant turn yet in June 2026. Merck agreed to pay more than $50 million to resolve more than 200 cases, closing out years of litigation over the HPV vaccine.
The deal follows a brutal stretch for plaintiffs, who lost most of their claims to a preemption ruling in 2025. Yet Merck chose to settle anyway rather than keep fighting case by case.
Gardasil sales hit $8.9 billion in 2023 before competition and litigation costs caught up with the brand. This article breaks down what the settlement covers, who qualifies, and what happens to the one case left standing.
What Is the Gardasil Lawsuit
The Gardasil lawsuit is federal and state litigation accusing Merck of failing to warn patients about serious autoimmune side effects. Plaintiffs allege the HPV vaccine caused conditions including POTS and POI in young women and girls.
Cases were consolidated into a multidistrict litigation in 2022. A separate track of cases proceeded in California state court, outside the federal MDL structure.
- Defendant: Merck and Co.
- Product: Gardasil and Gardasil 9
- Core allegation: failure to warn about autoimmune injury risk
Attorney Insight: Attorneys handling these claims point to the split between federal and state tracks as a key reason this case took years longer to resolve than expected.
Gardasil Lawsuit 2026 Update
The biggest 2026 development is Merck’s agreement to settle the bulk of Gardasil litigation for more than $50 million. The announcement came on June 4, 2026, confirmed through an emailed statement to Bloomberg News.
Merck said the deal would “end the litigation in its entirety” except for one remaining case. The settlement also resolved a closely watched California trial that had been scheduled for July 2026.
Bold callout: Merck’s own statement called the settlement amount “not material” to the company’s finances, despite covering more than 200 claims.
Attorney Insight: Attorneys handling these claims note that settling despite a winning legal position often signals a company wants to avoid the cost and unpredictability of appeals.
Who Qualifies for the Gardasil Lawsuit
Qualification for the settlement generally applies to plaintiffs who already had an active case in the MDL or California state court system. New claims outside those existing cases face a much harder path after the 2025 preemption ruling.
Eligible injuries center on two specific conditions tied to the litigation’s bellwether case selection.
| Condition | Description |
|---|---|
| POTS | Rapid heart rate increase upon standing, causing dizziness and fainting |
| POI | Reduced ovarian function or early menopause in women under 40 |
| Other autoimmune claims | Handled outside the primary bellwether track |
Attorney Insight: Attorneys handling these claims say the settlement’s scope, limited to existing filed cases, makes early legal consultation essential for anyone considering a new claim.
Litigation Watch: The June 2026 settlement resolves existing cases but does not clearly open a path for brand-new claims given the preemption ruling still on the books.
Gardasil Lawsuit Payout
The Gardasil lawsuit payout refers to individual compensation plaintiffs may receive from the more than $50 million settlement fund. Merck has not released a public payout schedule or per-claimant formula.
Settlement funds in mass tort cases are typically divided based on injury severity, medical documentation, and each plaintiff’s individual case value, not equally split among all claimants.
- Total settlement: more than $50 million
- Cases covered: more than 200
- Individual payout range: not yet disclosed publicly
Attorney Insight: Attorneys handling these claims caution that per-claimant estimates circulating online before an allocation formula is finalized are speculative at best.
Gardasil Settlement Amount Explained
The settlement amount is described by Merck as more than $50 million, covering the bulk of active Gardasil litigation. Bloomberg reported the figure on June 4, 2026, based on people familiar with the confidential negotiations.
Merck framed the amount as considerably less than what it expected to spend defending each case individually through trial and appeal.
- Confirmed source: Bloomberg News, June 4, 2026
- Company statement: settlement is “considerably less” than anticipated defense costs
- Admission of liability: none, per Merck’s public statement
Attorney Insight: Attorneys handling these claims note that mass tort settlements routinely include no admission of fault, which is standard and does not diminish the settlement’s real value to claimants.
Gardasil Lawsuit MDL Number and Court
The federal Gardasil lawsuit is consolidated as MDL No. 3036 in the U.S. District Court for the Western District of North Carolina. The Judicial Panel on Multidistrict Litigation transferred the cases there on August 4, 2022.
Judge Kenneth D. Bell has presided over the MDL since its creation, issuing the key rulings that shaped the litigation’s outcome.
| Detail | Info |
|---|---|
| MDL Number | 3036 |
| Full Case Name | In re: Gardasil Products Liability Litigation |
| Court | W.D. North Carolina |
| Presiding Judge | Kenneth D. Bell |
Attorney Insight: Attorneys handling these claims stress that knowing the presiding judge helps track how consistently a court has ruled on similar motions across a mass tort docket.
Gardasil POTS and POI Injury Claims
POTS and POI claims form the core injury allegations at the center of the Gardasil litigation. Plaintiffs alleged Gardasil triggered these conditions in previously healthy adolescents and young women.
Judge Bell’s 2025 ruling found insufficient scientific evidence linking Gardasil to these conditions to support a failure-to-warn claim under federal preemption standards.
- POTS symptoms: dizziness, fainting, elevated heart rate upon standing
- POI symptoms: early menopause, infertility, hormonal imbalance
- Court finding: evidence did not establish a “causal association” sufficient to proceed
Attorney Insight: Attorneys handling these claims note that a court finding insufficient evidence for one legal theory does not necessarily resolve the broader medical debate.
Litigation Watch: The settlement effectively closes the POTS and POI bellwether cases even though the underlying preemption ruling against them was never overturned.
Gardasil Lawsuit Preemption Ruling Explained
The preemption ruling is the March 11, 2025 order that gutted most failure-to-warn claims in the MDL. Judge Bell found that federal labeling law barred plaintiffs from arguing Merck should have added stronger warnings to Gardasil’s FDA-approved label.
The court noted only a handful of POTS reports existed before 2011, calling the evidence insufficient to support a scientific causal link.
- Ruling date: March 11, 2025
- Legal basis: implied federal preemption
- Result: dismissal of most failure-to-warn claims across the bellwether pool
Attorney Insight: Attorneys handling these claims say preemption rulings like this one are among the toughest defense wins in pharmaceutical litigation, since they can end cases before a jury ever hears the facts.
Gardasil Lawsuit Timeline
The Gardasil lawsuit timeline spans from the original MDL transfer through the 2026 settlement announcement. Key rulings arrived roughly a year apart, shaping the case’s final outcome.
August 4, 2022: JPML transfers federal Gardasil cases into MDL No. 3036 in the Western District of North Carolina.
March 11, 2025: Judge Bell grants summary judgment for Merck on failure-to-warn claims based on preemption.
September 4, 2025: Fourth Circuit affirms dismissal of bellwether cases in Needham v. Merck over untimely Vaccine Act petitions.
June 4, 2026: Merck agrees to pay more than $50 million to settle over 200 remaining cases.
Attorney Insight: Attorneys handling these claims note the roughly fifteen-month gap between the preemption ruling and the settlement reflects how long appeals and negotiations typically run in mass tort cases.
California Gardasil Lawsuit and Jennifer Robi Case
The California Gardasil case refers to Jennifer Robi’s lawsuit, which proceeded in Los Angeles Superior Court outside the federal MDL. Robi alleged Gardasil caused a heart condition that left her using a wheelchair.
Her case was scheduled for trial in July 2026 before the broader settlement resolved it along with the rest of the litigation.
- Plaintiff: Jennifer Robi
- Court: Los Angeles Superior Court
- Original trial date: July 2026, resolved by settlement before proceeding
Health Secretary Robert F. Kennedy Jr. had previously helped prepare Robi’s case as a plaintiffs’ attorney before joining the federal government. He later waived his right to a referral fee on the case.
Attorney Insight: Attorneys handling these claims say state court cases often move faster than an MDL, which can create separate settlement pressure even while federal proceedings continue.
Litigation Watch: The Robi case’s resolution through settlement, rather than trial, removed the single biggest wildcard that could have driven Merck’s exposure higher.
Vaccine Injury Compensation Program and Gardasil Claims
The Vaccine Injury Compensation Program, or VICP, is a federal system that generally must be used before filing a civil lawsuit over a covered vaccine injury. Gardasil is listed on the Vaccine Injury Table, making VICP the required first step for many claims.
The Fourth Circuit’s September 2025 ruling reinforced this requirement, dismissing bellwether petitions filed more than three years after symptom onset.
- Required filing window: within three years of first symptom, per the National Childhood Vaccine Injury Act
- Filing venue: U.S. Court of Federal Claims
- Consequence of missing the deadline: loss of jurisdiction for a later civil suit
Attorney Insight: Attorneys handling these claims say missed VICP deadlines have quietly ended more Gardasil claims than any single scientific dispute in this litigation.
Gardasil Lawsuit Filing Deadline
The filing deadline for a Gardasil claim depends heavily on when symptoms first appeared and whether a VICP petition was filed on time. The Vaccine Act generally requires filing within three years of the first symptom onset.
Missing that window can permanently bar a civil claim, regardless of how strong the underlying medical evidence might be.
- VICP deadline: three years from symptom onset
- Civil suit eligibility: dependent on completing VICP process first
- Current settlement: closed to new claimants outside existing filed cases
Attorney Insight: Attorneys handling these claims recommend documenting symptom onset dates immediately, since that single date often determines whether a claim can proceed at all.
Gardasil Lawsuit by State
Nearly all Gardasil litigation runs through two venues rather than fifty separate state court systems. The federal MDL in North Carolina absorbed the large majority of cases nationwide.
California stood out as the primary exception, hosting its own state court track that included the closely watched Robi case.
| Track | Location | Case Volume |
|---|---|---|
| Federal MDL | Western District of North Carolina | Majority of filed cases |
| State court | California (Los Angeles) | Smaller, high-profile track |
Attorney Insight: Attorneys handling these claims note that state court venues can sometimes reach trial faster than a crowded federal MDL docket.
What Type of Lawyer Handles the Gardasil Lawsuit
A pharmaceutical products liability attorney typically handles Gardasil claims, given the vaccine injury and federal preemption issues involved. These lawyers understand both mass tort procedure and the separate VICP filing requirements.
Because Gardasil sits on the Vaccine Injury Table, an attorney experienced in vaccine injury claims specifically can be critical before any civil suit is even possible.
- Core specialty: pharmaceutical product liability
- Secondary requirement: vaccine injury / VICP experience
- Case type: mass tort, not a traditional single-plaintiff lawsuit
Attorney Insight: Attorneys handling these claims say vaccine cases require a narrower specialty than typical product liability work, given the VICP’s strict procedural rules.
What Happens Next in the Gardasil Lawsuit
What happens next depends largely on the one case Merck’s settlement did not resolve. Details on that remaining claim have not been made public.
Separately, the settlement’s finalization will require formal court approval and an allocation process to determine individual payouts among the more than 200 covered claimants.
- Near-term: court approval of the settlement terms
- Mid-term: allocation formula determining individual payouts
- Unresolved: status of the one case excluded from the deal
Attorney Insight: Attorneys handling these claims expect the allocation process to take months, since settlement approval and fund distribution rarely move quickly in mass tort cases.
Litigation Watch: The settlement’s approval process, not the original preemption ruling, is now the detail most likely to determine when claimants actually see payment.
How to File a Gardasil Lawsuit Claim
Filing a new Gardasil claim today starts with the Vaccine Injury Compensation Program, not a civil lawsuit. Federal law generally requires exhausting that process before pursuing court action.
Given the 2025 preemption ruling and the narrow settlement scope, anyone considering a claim should get a case evaluation before assuming eligibility.
- Step one: confirm symptom onset date and check the three-year VICP filing window
- Step two: file a petition with the U.S. Court of Federal Claims if required
- Step three: consult a pharmaceutical injury attorney about remaining civil options
Attorney Insight: Attorneys handling these claims say the preemption ruling makes early legal guidance more important now than at any earlier point in this litigation.
Frequently Asked Questions
Is the Gardasil lawsuit still active in 2026?
Most of the litigation was resolved through a settlement announced on June 4, 2026.
Merck agreed to pay more than $50 million to settle over 200 cases.
One case remains unresolved, with details not yet public.
Who qualifies for the Gardasil lawsuit settlement?
The settlement generally covers plaintiffs who already had active cases in the MDL or California state court.
It centers on POTS and POI injury claims tied to the litigation’s bellwether pool.
New claims outside that group face a much harder path after the 2025 preemption ruling.
How much is the Gardasil lawsuit payout worth?
Merck agreed to pay more than $50 million total across more than 200 cases.
No public formula for individual payouts has been released yet.
Amounts will likely vary based on injury severity and case-specific documentation.
What is the Gardasil lawsuit MDL number?
The federal litigation is MDL No. 3036, In re: Gardasil Products Liability Litigation.
It is centralized in the U.S. District Court for the Western District of North Carolina.
Judge Kenneth D. Bell has presided over the case since 2022.
Do I need to file with the Vaccine Injury Compensation Program first?
Yes, federal law generally requires filing with the VICP before pursuing a civil lawsuit over a covered vaccine injury.
Gardasil is listed on the Vaccine Injury Table, making this step mandatory for most claimants.
Missing the three-year filing deadline can permanently bar a later civil claim.
Do I need a lawyer to get a Gardasil lawsuit payout?
Existing claimants in the settlement will likely go through their current attorney or the settlement’s claims process.
Anyone considering a new claim should consult a pharmaceutical injury attorney given the preemption ruling.
Legal guidance is especially important given the VICP’s strict procedural deadlines.
The Gardasil lawsuit reached a turning point in June 2026, closing most of the litigation Merck once fought hard to defend. Existing claimants should watch for settlement approval and allocation details in the coming months.
Anyone considering a new claim should speak with a pharmaceutical injury attorney promptly, given the tight VICP filing deadlines still in effect.
